PEMBROLIZUMAB , EIK1005 200mg Tablets, EIK1005 50mg Tablets, EIK1005 10mg Tablets clinical trials

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

This study is looking at a new drug, EIK1005, alone or with another approved cancer drug, Pembrolizumab. It’s for adults with certain advanced cancers to see how safe it is and how well it works. This is an early-stage study.